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Key points: 35 
1) Alcohol abuse is a risk factor for infectious complications. 36 
2) Alcohol has pleiotropic effects on the innate and adaptive immune system resulting in 37 
an immunosuppressive state. 38 
3) Alcohol modifies gut microbiome and increases gut permeability inducing 39 
translocation of bacteria and bacterial products. 40 
4) Sepsis is a leading cause of death in advanced alcoholic liver disease, particularly in 41 
severe alcoholic hepatitis. 42 
5) Opportunistic infections are increasingly described in severe alcoholic hepatitis, 43 
mainly in the context of corticosteroid treatment. 44 
6) Specific preemptive and/or prophylactic strategies against infectious agents in 45 
patients with advanced alcoholic liver disease should be designed to reduce the 46 
incidence of infection and to improve outcomes for these patients. 47 
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Summary 1 
Alcohol-related liver disease (ALD) remains the most important cause of death due to 2 
alcohol. Infections, particularly bacterial infections, are one of the most frequent and severe 3 
complications of advanced ALD, as alcoholic cirrhosis and severe alcoholic hepatitis (sAH). 4 
The specific mechanisms responsible of this altered host defence become to be deciphered. 5 
The aim of the present work is to review the current knowledge about infectious 6 
complications in ALD and the pathophysiological mechanisms, distinguishing the role of 7 
alcohol consumption and the contribution of different forms of ALD. To date, corticosteroids 8 
are the sole proven effective treatment in sAH but its impact on the occurrence of infections 9 
remains controversial. The combination of an altered host defence and corticosteroids 10 
treatment in sAH has been suggested as cause of the emergence of opportunistic fungal and 11 
viral infections. High level of suspicion with systematic screening and prompt, adequate 12 
treatment are warranted to improve outcome of those patients. Prophylactic or preemptive 13 
strategies in this high-risk population might be a preferable option due to the high short-term 14 
mortality rate despite adequate therapies but should be assessed in well-designed trials 15 
before clinical implementation.  16 
 17 
Introduction 18 
Excessive alcohol consumption is a major public health problem. In 2012, over three million 19 
deaths were attributed to alcohol consumption, corresponding to 5.9% of the total global 20 
deaths worldwide [1]. Alcohol is the most frequent cause of cirrhosis and accounts for 21 
approximately 40% of all liver transplants in Europe [2]. Although mortality from alcohol-22 
related liver disease (ALD) has declined over the last few decades in most Western 23 
European countries, ALD remains the most important cause of death due to alcohol [3]. 24 
The spectrum of ALD includes steatosis, steatohepatitis, progressive liver fibrosis, and 25 
cirrhosis and its complications [4]. At any stage, patients can develop a severe form of ALD 26 
  
4 
 
called alcoholic hepatitis (AH). Although most heavy drinkers develop steatosis, only a small 1 
subset of them will develop AH, and 10%-20% progress to cirrhosis [5]. Current management 2 
of ALD focuses on alcohol abstinence, nutritional support, and primary and secondary 3 
prevention of cirrhosis complications.  4 
AH is a clinical entity (which typically presents abruptly) characterized by recent onset (< 3 5 
months) of jaundice and typical histological lesions (macrovesicular steatosis with at least 6 
one of the following: ballooning hepatocytes, Mallory-Denk bodies and neutrophil infiltration, 7 
and intrasinusoidal fibrosis) in a patient with ongoing alcohol consumption (minimal threshold 8 
for women ≥ 40 g per day [3 drinks], for men ≥ 50-60 g per day [4 drinks]) [6]. The true 9 
prevalence of AH is currently unknown, due to the lack of systematic biopsy-driven 10 
diagnosis, but it has been reported to be as high as 20% in alcoholic hospitalized patients [7]. 11 
Its severe form (sAH; defined by a Maddrey discriminant function [mDF] ≥ 32) is associated 12 
with a high risk of mortality in the short-term (about 30% at 1 month). Although treatment for 13 
sAH remains a topic for debate, corticosteroids (prednisolone 40 mg per day) have been 14 
reported to result in a 14% reduction in 1-month mortality in patients with sAH in a meta-15 
analysis of 5 randomized controlled trials (RCT) [8]. A recent large RCT (STOPAH study) 16 
confirmed that corticosteroids significantly improved survival at 28 days when compared to 17 
placebo and after adjustment for different severity factors, but at lower level than expected, 18 
and this survival benefit was not maintained at 90 days and 1 year [9]. The potential efficacy 19 
of pentoxifylline in sAH, suggested by one small RCT, was not confirmed, either alone or in 20 
combination with corticosteroids, by larger trials [9–11]. The addition of N-acetylcysteine (for 21 
5 days and at doses equivalent to those used for acetaminophen overdose) to corticosteroids 22 
has been reported to further decrease (16%) mortality at 1 month compared to 23 
corticosteroids alone, but this benefit was lost at 6 months [12].  24 
A newly defined syndrome, called acute-on-chronic liver failure (ACLF), which is 25 
characterized by (hepatic and/or extrahepatic) organ failures and a high risk of death in the 26 
short term, occurs frequently in the context of alcoholic cirrhosis (60% in Europe) [13]. sAH 27 
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has been suggested to be a precipitating event for ACLF, mostly not biopsy-proven, because 1 
active alcohol consumption in the last three months is present in 20% of patients with ACLF 2 
[13]. 3 
Currently, infection, particularly bacterial infection, is one of the most frequent and severe 4 
complications of advanced liver disease [14–16]. In cirrhotic hospitalized patients with acute 5 
decompensation, bacterial infection was identified as the most common identifiable 6 
precipitating factor of ACLF [13]. The mechanisms underlying the increased risk of infection 7 
and infection-related death in advanced liver disease are complex and multifactorial, 8 
including impaired innate and adaptive immunity, bacterial overgrowth, dysbiosis, and 9 
translocation of gut-resident bacteria and bacterial products [16,17].  Very few well-designed 10 
prospective studies have specifically assessed the microbiological features of infection in 11 
ALD according to stage and clinical presentation. However, this information could help 12 
clinicians to better define preventive and empirical antimicrobial strategies, decrease risk of 13 
infection, and improve the prognosis of patients with severe forms of ALD. 14 
The aim of the present work is to review the current knowledge about infectious 15 
complications in ALD and the pathophysiological mechanisms by which ALD increases the 16 
risk of infection, distinguishing the role of alcohol abuse and the contribution of different 17 
forms of ALD, such as alcoholic cirrhosis and sAH. We will discuss the potential influence of 18 
treatment of sAH on the occurrence of infections. Finally, we will propose diagnostic and 19 
therapeutic recommendations, and suggest preemptive or prophylactic strategies that can be 20 
applied to clinical practice.  21 
Impact of alcohol and alcoholic liver disease on host 22 
defences 23 
Effects of alcohol exposure on immune cells 24 
Clinical observations and experimental data demonstrate that excessive alcohol use has 25 
broad and significant inhibitory effects on many key components of the immune system 26 
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(Figure 1) [18].  In addition to its “classical role” in host defence against pathogens, the 1 
immune system is integrally involved in processes such as sterile inflammation, recognition 2 
of modified and damaged host, and cancer surveillance [19]. To mount an effective immune 3 
response, coordination of the innate and adaptive immune systems is required between 4 
specific immune cell types and their regulatory pathways via direct cellular interactions or 5 
secreted molecules. The functions of most immune cells can be modulated by alcohol use 6 
that can undermine effective immune responses [18–20]. Cells of the innate immune system 7 
include neutrophils, monocytes, tissue-resident and recruited macrophages, dendritic cells, 8 
and natural killer (NK) cells. The adaptive immune system consists of different T lymphocyte 9 
subsets (CD4, CD8, Th1, Th2, Th17, Tregs), B lymphocytes, and NKT cells [21]. All immune 10 
cells produce various cytokines, chemokines, and inferferons (IFNs) that are key soluble 11 
mediators of immunity. The interactions between cells of the innate and adaptive immune 12 
systems are abundant and cannot be detailed in this review; thus, we focus on the effects of 13 
alcohol that are most fundamental in modulating immune responses.  14 
Innate immunity provides rapid recognition of pathogen-derived (pathogen-associated 15 
molecular patterns; PAMPs) or sterile danger signals (danger-associated molecular patterns; 16 
DAMPs) via pathogen recognition receptors [22]. These receptors, including toll-like 17 
receptors (TLRs), NOD-like receptors, and RXR receptors, lead to common signalling 18 
pathways resulting in two major innate immune responses: NF-kB –mediated activation of 19 
pro-inflammatory cytokines involved in anti-bacterial activities and interferon regulatory factor 20 
(IRF)-mediated production of Type I IFNs that mediate anti-viral effects.  These signalling 21 
pathways are affected by alcohol. Acute alcohol exposure was shown to inhibit 22 
lipopolysaccharide (LPS)-induced pro-inflammatory cytokine production by interfering with 23 
TLR4 signalling at multiple levels including TLR4 assembly in lipid rafts on the cell 24 
membrane, and activation of IRAK1/4 kinase and IKK kinases [23,24]. In contrast to acute 25 
alcohol exposure, chronic alcohol exposure results in increased pro-inflammatory cytokine 26 
production and TLR4 responsiveness due to alcohol-induced decreases in molecules that 27 
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otherwise mediate TLR tolerance [25]. Alcohol-induced inflammation is also amplified by 1 
increased IL-1ß production as result of inflammasome activation [26,27]. Despite an increase 2 
in pro-inflammatory cytokine production at tissue sites, antimicrobial defences are insufficient 3 
after chronic alcohol use and the pro-inflammatory cytokine environment contributes to host 4 
tissue damage instead of effective elimination of pathogens [18,28,29]. Alcohol use also 5 
inhibits the anti-microbial function of innate immune cells. Microbial killing by neutrophils is 6 
impaired and macrophage phagocytosis is reduced [18–21,28].   7 
Antigen presenting cells (APCs), including dendritic cells and monocytes, play a central role 8 
in connecting innate and adaptive immune responses through their antigen presentation 9 
function in which pathogen-derived specific antigens are presented to T lymphocytes to 10 
trigger T cell activation and proliferation [18–20].  Effective antigen presentation is dependent 11 
on expression of MHC class II molecules and co-stimulatory molecules CD80/86 on antigen 12 
presenting cells [18–20]. However, all of these components of antigen presentation function 13 
can be negatively affected by alcohol abuse. In vitro and in vivo studies suggest that even 14 
acute alcohol exposure inhibits the T cell stimulatory function of human monocytes [18–15 
21,28]. Chronic alcohol exposure has also been shown to inhibit monocyte antigen 16 
presentation and antigen-specific T cell activation in vitro [18–21,28].  Dendritic cells are 17 
highly specialized immune cells of bone marrow origin that undergo maturation in the local 18 
tissue environment in response to pathogen and tissue-derived signals to assume full 19 
functional activity. Myeloid dendritic cells have been shown to be inhibited in reaching their 20 
full maturation by alcohol in vitro resulting in an immature phenotype with a predominantly 21 
inhibitory rather than an activating function on T cells [30].  The inhibitory effects of alcohol 22 
are linked to alcohol-induced increases in IL-10 and decreases in IL-12 production, cytokines 23 
regulating T cell activation and APC function. Plasmacytoid dendritic cells, while small in 24 
numbers, play a critical role in anti-viral immune responses due to their capacity to produce 25 
large amounts of IFN-α. Studies show that alcohol impairs IFN production pathways not only 26 
in plasmacytoid dendritic cells but even in other immune cell types in the peripheral blood 27 
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mononuclear cell population in response to typical viral activation signals induced by TLR3, 1 
TLR7/8, or TLR9 stimulation [31]. 2 
Alcohol-related cirrhosis-associated immune dysfunction (CAID) 3 
The course of cirrhosis, regardless of its etiology, is complicated by cirrhosis-associated 4 
immune dysfunction (CAID), which constitutes the pathophysiological hallmark of the 5 
increased susceptibility to bacterial infection distinctive of cirrhosis [32]. The term CAID 6 
includes two syndromic alterations that are present in cirrhosis: i) immunodeficiency, due to 7 
an impaired response to pathogens at different levels of the immune system, and ii) systemic 8 
inflammation, as a consequence of persistent and inadequate stimulation of immune system 9 
cells (Figure 2). Although the main characteristics of CAID are present in cirrhosis of any 10 
cause, specific etiologies, i.e. alcohol, can introduce distinctive features in the phenotypic 11 
expression of CAID. 12 
Cirrhosis is associated with several abnormalities in the innate and adaptive components of 13 
the immune system response that compromise the surveillance role of the liver and the 14 
functions of circulating immune system cells, leading to a state of acquired 15 
immunodeficiency. The structural derangements of cirrhosis, including sinusoidal fibrosis and 16 
capillarization, septal fibrosis with portal-systemic shunts, and Kupffer cell loss or damage, 17 
which are especially prominent in alcoholic liver disease, diminish the clearance of 18 
endotoxins and bacteria from the blood, leading to bacteremia, and persistent immune 19 
system stimulation. A lack of Kupffer cells or of their complement receptors results in 20 
uncontrolled bacteremia and increased host death in experimental models [33]. In agreement 21 
with these findings, diminished reticulo-endothelial system function in cirrhosis has been 22 
associated with a greater risk of bacterial infection and lower survival [34]. Cirrhosis also 23 
impairs the synthesis of innate immunity proteins and of pattern recognition receptors, 24 
reducing the bactericidal capacity of phagocytic cells. Given the large functional reserve of 25 
the liver, lowered serum levels of these proteins are only evident in patients with advanced 26 
cirrhosis and ascites. Indeed, ascites due to cirrhosis increases susceptibility to bacterial 27 
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infection, and this has been related to low opsonic activity as a result of reduced 1 
concentrations of C3, C4, and CH50 in serum and ascitic fluid [35]. 2 
Defects in the immune system due to CAID are particularly evident in the function of 3 
circulating immune system cells. The circulating populations of most immune system cells 4 
are reduced in number, especially those of neutrophils and T lymphocytes, due to splenic 5 
pooling and also due to depressed bone marrow production caused by chronic alcohol 6 
consumption. In contrast, cirrhosis is associated with monocytosis, as the main increase in 7 
the pro-inflammatory non-classical CD14+CD16+ subset [36,37]. Besides reducing their 8 
circulating numbers, cirrhosis damages the function of APCs by compromising their 9 
bactericidal ability and their delivery to the infection sites. Neutrophils in cirrhosis show 10 
impaired phagocytosis of opsonized bacteria [38–41], including defective superoxide anion 11 
O2- production and myeloperoxidase activity and a lower response to peptidoglycan 12 
recognition protein [38,42,43], as well as impaired chemotaxis to the infection focus through 13 
decreased transendothelial migration [39,40]. Of note, and as is true for other circulating 14 
immune system cells, monocyte and neutrophil dysfunction has been linked to persistent in 15 
vivo stimulation, as shown by an increased resting respiratory burst, particularly observed in 16 
patients with higher serum levels of pro-inflammatory cytokines [40]. Circulating monocytes 17 
of patients with alcoholic cirrhosis produced higher amounts of pro-inflammatory cytokines 18 
and chemokines in response to LPS but have a defect in the induction of IFN-mediated 19 
program [44,45]. The defective APC function observed in cirrhosis is more evident in that 20 
caused by alcohol, since ethanol ingestion specifically damages the bactericidal and 21 
chemotaxis activity of neutrophils and the migration ability of APCs [46–48]. The T cell 22 
compartment is also depleted in cirrhosis, a fact that affects T-helper (Th) and T-cytotoxic 23 
(Tc) cells [49–52], and, regardless of disease etiology, is more pronounced in the naive than 24 
in the memory compartment [49,53,54]. Additionally, circulating T lymphocytes are activated 25 
in vivo and show diminished proliferation [55–57]. Circulating NK cells are also defective in 26 
cirrhosis and exhibit poor responses to cytokine stimulation [58]. Thus, characteristic features 27 
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of cirrhosis, particularly that caused by alcohol, include reduced numbers and impaired 1 
bactericidal ability of circulating immune system cells, along with their activation and 2 
increased production of pro-inflammatory cytokines, as further discussed below.  3 
A distinctive feature of CAID is the dynamic coexistence of acquired immunodeficiency and 4 
systemic inflammation. The latter results from the persistent stimulation of immune system 5 
cells and is defined by the increased production and enhanced serum levels of pro-6 
inflammatory cytokines and the up-regulation of the expression of activation markers in 7 
immune cells. The activated circulating immune system cells eventually become the major 8 
contributors to increased serum concentrations of pro-inflammatory cytokines such as TNFα, 9 
TNFα soluble receptors I and II, IL-1β, IL-6 and IFNγ, IL-17, as well as ICAM-1 and VCAM-1 10 
present in experimental and human cirrhosis [49,59,60]. The severity of this state of systemic 11 
inflammation parallels that of the cirrhosis itself, as assessed by Child-Pugh score [61–66], 12 
and it is particularly intense in cirrhosis with ascites. 13 
A main part of these cirrhosis-associated immune alterations are dependent of humoral 14 
factors and can be improved by interventions. Circulating monocytes of patients with 15 
alcoholic cirrhosis, cultured in vitro without stimulation, lost their enhanced ability to produce 16 
pro-inflammatory cytokines, returning to levels of monocytes from healthy subjects [67]. In 17 
the same way, plasma from patients with cirrhosis induced neutrophil phagocytic dysfunction 18 
in cells from healthy subjects [40]. Different experiments suggested that the main factors 19 
responsible of CAID are circulating PAMPs coming from the intestine (see below). The 20 
suppression of enteric aerobic bacterial load by intestinal decontamination with antibiotics 21 
normalizes the expansion of circulating activated immune cells and attenuates the pro-22 
inflammatory cytokine production [49]. 23 
Evidence of superimposed immune dysfunctions in severe alcoholic hepatitis 24 
(sAH) 25 
There is a clear paradox in patients with sAH, whereby they can transition from evidence of 26 
marked systemic inflammatory response syndrome characterised by a pro-inflammatory 27 
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cytokine milieu to immune failure, increased risk of infection, and mortality suggesting that 1 
the syndrome may well have distinct phenotypes from an immunological perspective (Figure 2 
2) [68]. From a clinical and pathophysiological perspective, it is useful to consider sAH in 3 
terms of whether the patient has associated ACLF, because this can change the outlook for 4 
patients. Patients with ACLF due to sAH have a high risk of multiple organ failure and 5 
mortality [13]. Recent studies have started to describe the immunologic disturbances 6 
associated with sAH with and without ACLF and this is summarised below. 7 
Cytokine milieu in patients with sAH  8 
The best data describing cytokine profiles in sAH come from analysis of the CANONIC study 9 
[69]. This study showed that patients with sAH and ACLF have a very different cytokine 10 
profile to that of patients without ACLF. In patients with ACLF, both pro- (TNF-α, IL-6, and IL-11 
8) and anti-inflammatory cytokines (IL-10 and IL-1 receptor antagonist (Ra)) were markedly 12 
elevated compared to patients without ACLF. In those with ACLF, the pattern of changes in 13 
cytokines was different dependent upon whether they had sAH or not. Patients with sAH 14 
showed predominantly elevations in IL-8, clearly indicating that the cytokine milieu in sAH is 15 
specific [69]. In fully interpreting these data, one must take into account that these patients 16 
were not classified with liver biopsies.  17 
The data suggest that although there is evidence of significant systemic inflammation, there 18 
is a simultaneous increase in the anti-inflammatory milieu making the risk of ‘immune failure’ 19 
and infection high. It is, therefore, not surprising that attempts to inhibit TNF-α using anti-20 
cytokine strategies have failed by inducing infectious complications [70].  21 
Cellular basis of immunologic dysfunction in sAH.  22 
Almost all cell types have been shown to be deranged in patients with sAH affecting both 23 
adaptive and innate immunity. The main observations are summarised below (Table 1). 24 
Adaptive Immunity 25 
Lymphocytes: Studies on peripheral blood mononuclear cells from patients with sAH 26 
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showed that T cells from these patients produced less IFN-γ in response to LPS and had 1 
greater numbers of IL-10–producing T cells compared to patients with alcoholic cirrhosis. 2 
This was shown to be associated with upregulation of programmed cell death 1 (PD1) and 3 
the T cell immunoglobulin and mucin domain– containing protein 3 (TIM3), which are 4 
inhibitory receptors that regulate the balance between protective immunity and immune-5 
mediated damage by the host. Antibodies against PD1 and TIM-3 restored interferon 6 
production and decreased IL-10 producing T cell populations, providing potential therapeutic 7 
targets for the future [71].  8 
Innate Immunity 9 
Monocytes/Macrophages: The first comprehensive study of immune response in patients 10 
with ACLF was performed by Wasmuth et al., who studied a mixed group of patients, most of 11 
whom had alcoholic cirrhosis and possibly sAH. The study showed evidence of reduced 12 
TNF-α production from monocytes in response to LPS and reduced HLA-DR expression, 13 
which is known to be important for a fully functional innate immune response. The authors 14 
hypothesised the presence of an ‘immune paralysis’ in the patients that had associated 15 
ACLF [72]. Many subsequent studies have confirmed these initial observations pointing to 16 
the mixed inflammatory responses and have explored potential mechanisms. In a mixed 17 
population of patients, but particularly in the patients with sAH, O’Brien et al. also showed 18 
evidence of immune dysfunction affecting monocyte-derived macrophages and pointed to a 19 
potential inhibitor role of prostaglandin-E2 [73]. Bernsmeier et al. extended these earlier 20 
observations and their data suggested that the immune failure in ACLF patients may be 21 
related to increased expression of the MER tyrosine kinase (MERTK) on circulating 22 
monocytes. MERTK is a key negative regulator of innate immune responses and plays a 23 
central role in the resolution of inflammation through inhibition of pro-inflammatory responses 24 
and promoting the clearance of apoptotic cells [74]. These investigators also showed that, 25 
although the monocytes were able to phagocytose bacteria, they were not able to kill the 26 
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microbes. This defect was associated with increased risk of infection and death. This 1 
reduced killing ability was suggested to be due to reduced NADPH oxidase [75].  2 
Neutrophils: Neutrophils in patients with sAH have historically been shown to be primed, 3 
suggesting a potentially pro-inflammatory phenotype, while other studies have suggested 4 
they are dysfunctional and unable to phagocytose and kill bacteria. In a carefully performed 5 
study, including patients with biopsy-proven AH, Mookerjee et al. reported a wide range of 6 
neutrophil functions. In those that developed sepsis, organ failure, and had a risk of mortality, 7 
neutrophilic resting oxidative bursts were markedly increased and phagocytosis was 8 
markedly reduced [76]. Experimental data indicate that neutrophil dysfunction in sAH may be 9 
due to increased circulating LPS and that dysfunction may be potentially reversible with the 10 
removal of LPS or using TLR4 inhibitors, providing the basis for potentially novel therapies 11 
[77]. More recently, Boussif et al. confirmed the bactericidal defect in the neutrophils of 12 
patients with decompensated alcoholic cirrhosis, including about 40% who had sAH, and 13 
showed that this was related to a defect of myeloperoxidase release and AKT/P38-MAPK 14 
pathway [78]. They went on to show restoration of this pathway with agonists of the TLR7/8 15 
pathway providing a potential therapeutic target. In another study, targeting PD1 and also 16 
TIM-3 was able to restore neutrophil function as was observed with lymphocytes [71]. 17 
The impact of alcohol and alcoholic liver disease on the intestine 18 
Alcohol damages the intestinal barrier and increases permeability, which then facilitates the 19 
passage of bacteria and bacterial products to the internal milieu. Indeed, LPS and bacterial 20 
DNA increase in serum after binge and chronic alcohol consumption in healthy subjects and 21 
in experimental models [79,80]. Ethanol and/or its metabolites, such as acetaldehyde, have a 22 
direct effect on tight junction complex, by redistribution of occludin and dissociation from its 23 
actin cytoskeleton, and on adherens junction [81]. Ethanol also causes an absolute increase 24 
in aerobic and anaerobic bacteria load, especially in the proximal gut, as well as dysbiosis, 25 
which is characterized by a relative decrease of Firmicutes and an increase of Bacteroidetes 26 
and Proteobateria [82,83]. Such an effect of alcohol on luminal bacteria seems to be 27 
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mediated by a reduction in the synthesis of antimicrobial peptides, such as lectinReg3, by 1 
epithelial and Paneth cells [83,84]. Intestinal inflammation with augemented synthesis of 2 
mediators that increase permeability could be the mechanism by which dysbiosis mediates 3 
barrier damage by ethanol. In this regard, intestinal permeability and recruitment of TNF-a 4 
activated monocytes in the lamina propria of mice fed with ethanol are reduced by 5 
administration of non-absorbable antibiotics or by using mutant mice for defective for TNF 6 
receptor type I or for myosin light-chain kinase, a downstream target of TNF-α [85]. The 7 
proposed model involves dysbiosis and bacterial overload due to reduced synthesis of 8 
antimicrobial peptides by ethanol, and increased permeability secondary to damage of the 9 
intestinal barrier by inflammatory mediators that allows the passage to the systemic 10 
circulation of bacteria and their products. 11 
In cirrhosis, the deleterious effect of alcohol in the intestinal barrier is added to that caused 12 
by cirrhosis itself. Indeed, advanced cirrhosis is characterized by a profound damage of the 13 
interrelated levels of defense of the intestinal barrier, which results in an increased 14 
translocation rate of enteric bacteria and/or their products [87–89]. Specifically, cirrhosis 15 
leads to increased intestinal permeability due to compromised epithelial integrity, intestinal 16 
bacterial overgrowth and dysbiosis, caused by disruption of host microbiota homeostasis and 17 
intestinal and general immune defense impairment [89,90]. Concurrent damage to these 18 
three levels of defense explains the referred high rate of translocation of live bacteria and 19 
PAMPs from the gut that occurs in advanced human and experimental cirrhosis [49]. 20 
A specific dysbiosis has been observed in patients with sAH [91]. The transfer of human 21 
intestinal microbiobiota coming from patients with sAH induced increased gut permeability 22 
and BT in ethanol-exposed mice compared to intestinal microbiotia of patients without sAH. 23 
Moreover, more than 90% of patients with sAH have detectable circulating bacterial DNA, 24 
which is substantially higher than rates observed in other forms of decompensated cirrhosis 25 
[92]. Interestingly, pretreatment levels of circulating bacterial DNA predict the development of 26 
infection in patients with sAH treated with corticosteroids and high serum LPS levels predict 27 
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the occurrence of in-hospital infection, suggesting that translocation plays a central role in 1 
the susceptibility to spontaneous infection [92,93].  2 
Epidemiological, microbiological, and prognostic data on 3 
infections in patients with alcohol abuse and/or alcoholic 4 
liver disease 5 
Alcohol abuse is a risk factor for infections 6 
Individuals who chronically drink excessive amounts of alcohol are usually subclinically 7 
“immunocompromised” and this immune dysfunction becomes clinically significant only when 8 
a secondary insult occurs [18,28]. Clinical evidence indicates that chronic alcohol 9 
consumption increases the risk of viral and bacterial infections. For example, the combined 10 
immunosuppressive effects of alcohol and human immunodeficiency virus (HIV) infection are 11 
well described [94,95]. Excessive alcohol use is associated with increased risk of chronic 12 
hepatitis C infection and immunologic studies have found that alcohol and hepatitis C virus 13 
(HCV) are synergistic in inhibition of antigen-specific immune responses and activation of 14 
non-specific pro-inflammatory responses [96–99].  15 
Certain bacterial infections are clearly more prevalent in individuals who abuse alcohol. 16 
Alcohol use has negative effects on pulmonary infections with Legionella pneumophila and 17 
Mycobacterium tuberculosis and predisposes patients to systemic dissemination of 18 
tuberculosis [29,100]. Pneumonia related to Gram-negative bacilli (GNB), such as Klebsiella 19 
pneumoniae, or Gram-positive cocci (GPC), such as Streptococcus pneumoniae, is more 20 
common in alcoholics compared to non-alcoholic individuals [101]. In patients with 21 
community-acquired pneumonia, a history of alcohol abuse is associated with infections 22 
caused by virulent GNB such as Pseudomonas aeruginosa and Acinetobacter species [102]. 23 
Infectious complications in the context of alcoholic cirrhosis 24 
Bacterial infections constitute a major complication of alcoholic and non-alcoholic cirrhosis 25 
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and are associated with high mortality rates [14–16,103]. Infections can occur in 1 
compensated and decompensated cirrhosis, frequently precipitate clinical decompensations 2 
(variceal hemorrhage, hepatic encephalopathy), and may further deteriorate decompensated 3 
patients (variceal rebleeding and hepatorenal syndrome [HRS]). Bacterial infections are also 4 
a major precipitating event of ACLF, a syndrome frequently observed in alcoholic patients 5 
[13,104]. It is, therefore, not surprising that bacterial infection is associated with increased in-6 
hospital mortality (4-5 fold), and risk of death from sepsis (2-fold) [103].  7 
Well-known clinical risk factors for the development of bacterial infections are poor liver 8 
function, upper gastrointestinal bleeding, low protein ascites, prior SBP, and hospitalization 9 
(especially if associated with invasive procedures and intensive care unit admission) [14,15]. 10 
Alcoholic cirrhosis, active alcohol consumption and poor nutritional status have also been 11 
suggested as predisposing factors to infection.  12 
Risk of bacterial infection associated with alcoholic cirrhosis and active alcohol 13 
consumption 14 
Several studies have reported a higher frequency of bacterial infections in patients with 15 
alcoholic cirrhosis when compared with non-alcoholic liver disease [105–107]. In the study by 16 
Rosa et al., 39% of alcoholic patients developed a bacterial infection at admission or during 17 
hospitalization in comparison to 28% of non-alcoholic patients. However, differences in the 18 
prevalence of infections were only statistically significant in patients with relatively preserved 19 
liver function (Child-Pugh A/B): 37% vs. 23% in alcoholic and non-alcoholic patients, 20 
respectively (p=0.02), but not in Child-Pugh C patients (49% each) [105]. Recently, Sargenti 21 
et al. evaluated the potential role of alcoholic etiology in the development, clinical type, and 22 
prognosis of bacterial infections in a population-based longitudinal cohort of 633 cirrhotic 23 
patients. During a median follow-up of 36 months, severe bacterial infections (those resulting 24 
in or occurring during hospitalization) developed more frequently in patients with alcoholic 25 
cirrhosis (45% vs. 28%, p<0.05). Frequency was especially high in those with active 26 
alcoholism (51% vs. 38%, p=0.03). However, after adjusting for confounders (MELD score 27 
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and age), alcoholic cirrhosis and active alcoholism were not found to be independently 1 
associated with the development of bacterial infections [106]. An additional study has 2 
evaluated the impact of alcoholic etiology and active alcohol consumption on the risk of 3 
infection after variceal bleeding. Patients with alcoholic cirrhosis and Child-Pugh A/B had 4 
significantly more infections than those with cirrhosis of other etiologies (Child-Pugh A: 10% 5 
vs. 0%; Child-Pugh B: 24% vs. 3.5%, p<0.05) in spite of antibiotic prophylaxis. Among low-6 
risk patients (Child-Pugh A), the risk of infection was significantly higher in patients with 7 
active alcohol consumption (21% vs. 0% in non-drinkers, p=0.01). Alcohol consumption was 8 
identified as an independent risk factor for infection [107]. The results of these three studies 9 
suggest that alcoholic etiology and alcohol consumption act as risk factors for bacterial 10 
infections mainly in cirrhotic patients without advanced liver dysfunction. In line with this 11 
hypothesis, other studies do not support the role of alcoholic cirrhosis or of active alcohol 12 
consumption as risk factors for the development of spontaneous or secondary bacterial 13 
infections in cirrhosis [13,108–116]. Poor nutritional status and low serum cholesterol levels, 14 
conditions frequently observed in alcoholic patients with and without cirrhosis, have also 15 
been associated with an increased risk of infection, multiple organ dysfunction and poor 16 
prognosis [117–119]. 17 
Type of bacterial infections and microbiology 18 
Spontaneous bacterial peritonitis (SBP) and urinary tract infections (UTI) are the most 19 
frequent infections occurring in cirrhosis followed by pneumonia, cellulitis, and bacteremia. A 20 
higher risk of bacteremia and meningitis has been reported in patients with alcoholism [120–21 
122]. A recent population-based study also suggests that alcoholic cirrhosis predisposes 22 
patients to the development of pneumonia (17% vs. 8% in non-alcoholic cirrhosis, p=0.02) 23 
[106]. A post-hoc analysis of a study involving 615 non-SBP infections in cirrhosis supports 24 
that pneumonia (16% vs. 11%, p=0.05) and cellulitis (19% vs. 12%, p=0.02) tend to occur 25 
more frequently in patients with alcoholic cirrhosis [123]. Finally, SBP episodes caused by 26 
Listeria monocytogenes have been sporadically reported in patients with cirrhosis, especially 27 
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in those of alcoholic etiology [124]. 1 
Antimicrobial resistance has become a major global healthcare problem that is especially 2 
relevant in decompensated cirrhosis [125]. Alcoholism has been reported to be associated 3 
with infections caused by antibiotic-resistant organisms in non-cirrhotic individuals [126,127]. 4 
However, it is unclear whether this is also true for patients with alcoholic liver cirrhosis. 5 
Current/recent contact with the healthcare system, especially nosocomial infection, long-term 6 
quinolone prophylaxis, recent use of antibiotics (3 months), and infection by multidrug-7 
resistant bacteria in the last 6 months are all well-known risk factors of infections caused by 8 
multidrug-resistant bacteria in cirrhosis [125,128,129]. A recent cohort study has also 9 
identified alcoholic etiology as a potential risk factor for bacterial infections caused by 10 
resistant strains. Resistance to piperacillin-tazobactam, third-generation cephalosporins, and 11 
carbapenems was more common in infections occurring in alcoholic than in non-alcoholic 12 
cirrhosis (13% vs. 5%, p=0.06 and 12 vs. 2%, p=0.009, respectively) in this series. However, 13 
alcoholic etiology was only identified as an independent predictor of infections caused by 14 
Gram-positive bacteria but not of infections caused by multidrug-resistant organisms 15 
(MDROs) [106]. No other study to date has reported alcoholic etiology as a risk factor for 16 
antimicrobial resistance in the cirrhotic population.  17 
Impact of alcoholic etiology and active alcohol consumption on prognosis of bacterial 18 
infections 19 
Published data on the clinical impact of alcoholic etiology and alcohol abuse on infection-20 
related complications (acute kidney injury (AKI), severe sepsis, and ACLF) and short-term 21 
mortality in cirrhosis are controversial. Initial studies reported a similar prevalence of 22 
alcoholic cirrhosis in patients with and without infection-related AKI and with and without 23 
systemic inflammatory response syndrome [130,131]. In contrast, a recent study has shown 24 
a higher propensity of infected patients with alcoholic cirrhosis to develop infection-related 25 
AKI (57% vs. 40%, p=0.002), sepsis (78% vs. 66%, p=0.01), and severe sepsis (44% vs. 26 
25%, p=0.001) [106].  27 
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Infection-related and infection-unrelated ACLF occurs more frequently in patients with 1 
alcoholic cirrhosis than in those with non-alcoholic cirrhosis, especially in those with active 2 
alcohol consumption [13,132]. Sargenti et al, recently published a population-based 3 
investigation assessing the impact of bacterial infections on the course of compensated and 4 
decompensated cirrhosis as well as the occurrence and predictors of infection-related ACLF. 5 
The study was performed between 2001-2010 in patients residing in an area of Sweden of 6 
600,000 inhabitants. Bacterial infections (n=398) developed in 241 patients (106 with 7 
compensated cirrhosis and 135 with decompensated cirrhosis). ACLF occurred in 95 patients 8 
and was associated with a high mortality rate (49%). MELD score, active alcohol 9 
consumption, and healthcare-associated infection were identified as independent predictors 10 
of infection-related ACLF [132]. 11 
The impact of alcoholic etiology and active alcoholism on infection-related short-term 12 
mortality in cirrhosis is unclear with some studies reporting a worse outcome in infected 13 
patients with alcoholic cirrhosis [121,133] and others showing no difference between groups 14 
[108,109,120,131,134]. The negative impact of alcohol on prognosis of infected patients with 15 
cirrhosis is probably linked to the increased risk of infection-related ACLF. 16 
Clinical characteristics of infections in severe alcoholic hepatitis (sAH)  17 
Infection is one of the main complications of sAH, as well as one of the major causes of 18 
mortality in this setting. In a study by Louvet et al., up to 25% of patients with sAH were 19 
found to have an active infection at admission before corticosteroid treatment following 20 
systematic screening [135]. Moreover, incidence of infection has been evaluated in 21 
therapeutic trials as part of secondary outcome or adverse event analyses of the studied 22 
intervention. A meta-analysis of 12 randomized trials found a cumulative incidence of 23 
infection of 20% in patients with sAH during 28-day corticosteroid treatment period [136]. 24 
Others have reported incidences as high as 50% to 67% during a 3-month follow-up (Table 25 
2) [93,137]. 26 
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Infections accounted for 24% of all deaths in the largest trial to date on sAH [9]. Infected 1 
patients with sAH suffer from a further increase in mortality of 30% at 2 months. If 2 
responders to corticosteroids get an infection, they have survival similar to that of non-3 
responders [135]. Reported mortality attributable to infection is probably underestimated 4 
because even other causes of mortality in sAH, such as liver-related events/ failure and 5 
gastrointestinal bleeding may be precipitated by or occur concomitant to an unidentified 6 
infection. 7 
Contribution of treatment to infections in sAH 8 
One of the major controversies of the past few years has been whether corticosteroids, used 9 
for the treatment of sAH, induce infection or whether severe liver injury per se accounts for 10 
the development of sepsis. Unfortunately, clear evidence is lacking, making it impossible to 11 
firmly respond to this question. Infection is not an independent predictor of outcome and is 12 
closely related to non-response to corticosteroids [135]. This suggests that severe liver 13 
dysfunction caused by the lack of efficacy of medical treatment is the main driver of mortality 14 
and infection, rather than corticosteroids alone. Nevertheless, it is tempting to suggest that 15 
corticosteroids might enhance infection because they are known to induce infectious events 16 
in other fields, mainly by inducing a defect in lymphocyte signaling. Data from randomized 17 
controlled trials (RCTs) help answer this question. The RCT STOPAH reported a higher 18 
incidence of infection in patients treated with prednisolone (13% vs. 7%) than in patients 19 
without prednisolone, whereas prednisolone use was associated with lower mortality [9]. 20 
Recently, a meta-analysis from 12 RCTs has shown that patients treated with corticosteroids 21 
had no increased risk of infection or higher mortality from infection than those treated with 22 
placebo [136]. However, in this meta-analysis, opportunistic infections, especially fungal, 23 
seemed to be more frequent, despite a low occurrence of cases. Opportunistic infections, in 24 
particular invasive aspergillosis, have also been reported by other teams but the link with 25 
steroid use has not been investigated in these studies [138,139].   26 
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Few data are available on the other treatment options for severe alcoholic hepatitis. It is 1 
important to remember that no pharmacological strategy except prednisolone has been 2 
shown to be effective in improving short-term survival in patients with severe alcoholic 3 
hepatitis. Several trials have shown that pentoxifylline use, either alone or in combination 4 
with corticosteroids, did not seem to affect the incidence of infection [9,11,140].  5 
Pentoxifylline use was associated with a lower incidence of infection in patients with 6 
decompensated cirrhosis, including 40% with severe alcoholic hepatitis [141]. However, 7 
pentoxifylline does not improve survival in severe alcoholic hepatitis and the rationale for its 8 
use is very limited. Similar results (i.e. lower incidence of infection without significant 9 
improvement in survival) have been observed in patients treated with N-acetylcysteine and 10 
prednisolone compared to corticosteroids alone [12]. TNF-α inhibitors have been shown to 11 
promote the risk of mortality and infection, either alone or associated with corticosteroids and 12 
must no longer be used [70,142]. In a single-center RCT, addition of granulocyte colony-13 
stimulating factor (G-CSF) to pentoxifylline improved survival of patients with sAH compared 14 
to pentoxifylline alone [143]. In another RCT, the G-CSF-induced survival benefit of patients 15 
with ACLF (57% had sAH) seems to be related to the prevention  of sepsis [144]. 16 
Bacterial infections in sAH 17 
Bacterial infections represent the vast majority (nearly 80%) of infectious episodes in the 18 
context of sAH but invasive fungal infections are increasingly reported (up to 20% in some 19 
reports) [138].  20 
Urinary tract infections (UTI) and respiratory infections seem to occur more commonly during 21 
sAH, compared to cirrhosis, where SBP is predominant [93,128,145]. Based on a study by 22 
Louvet et al., the sites of infection vary between admission and follow-up [135]. Indeed, at 23 
baseline, SBP or spontaneous bacteremia (SB) occurred more frequently, followed by UTI, 24 
respiratory and cutaneous infection episodes. After or during corticosteroid treatment, a shift 25 
towards respiratory infections was noted (40% of all episodes), but SBP or SB and UTI 26 
decreased, while cutaneous infections remained stable. Concerning in-hospital infections 27 
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only, Altamirano et al. reported pneumonia as being the most frequent (26%), followed by 1 
UTI and skin and soft tissue infection, while SBP was present only in 6% of infected patients 2 
[146]. Interestingly, the STOPAH trial also found a high prevalence of respiratory infections, 3 
representing 50% of all infections during follow-up [9]. A possible interpretation for this shift 4 
from spontaneous infections, frequently seen as a hallmark of cirrhosis, towards respiratory 5 
infections, may be corticosteroid treatment, nosocomial origin, and/or intensive care unit 6 
admission.  7 
Data regarding pathogens are scarce in sAH studies. Nearly, half of infectious episodes are 8 
nosocomial [135,137]. In a small study on patients with AH, GNB, mainly Escherichia coli, 9 
represented 75% of all isolated bacteria, as in cirrhotic patients without AH [147]. In another 10 
report, isolated bacteria were 67% GNB and 29% GPC, E. coli being the most frequently 11 
isolated organism, followed by Staphylococcus aureus [137]. These observations are 12 
confirmed by the STOPAH trial where GNB, in particular E. coli, was the most isolated 13 
microorganism [92]. Another small study, focusing on bloodstream infections, found a high 14 
prevalence of GPC (44%), while GNB were present in only 22% [148]. MDROs were isolated 15 
in 24% of patients with sAH [137]. Moreover, according to a large United States database, 16 
Clostridium difficile infection, among patients with AH followed-up during hospitalization, had 17 
a prevalence of 1.6%, which was 1.5-fold higher than that of hospitalized patients without AH 18 
[149]. 19 
Invasive fungal infections (IFI) in sAH 20 
IFI are common complications in deeply immunocompromised patients. In patients with sAH 21 
mostly treated by corticosteroids, the prevalence of IFI is reported to be as high as 14% to 22 
26% [138,150]. The diagnosis of IFI and distinguishing infection from colonization in these 23 
patients is challenging. Therefore, the prevalence of IFI is directly dependent on the intensity 24 
of diagnostic screening. 25 
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Invasive aspergillosis (IA) 1 
One study of a prospective cohort of 94 patients with biopsy-proven sAH who underwent 2 
systemic screening (frequent galactomannan [GM] testing, chest and cerebral CT, 3 
bronchoalveolar lavage [BAL]) for IA reported an IA incidence of 16% after a follow-up of 4 
three months [138]. In this study, risk factors for acquisition of IA were ICU admission and 5 
baseline MELD score ≥ 24. The diagnosis was made after 6 to 80 days of corticosteroid 6 
initiation (median of 25 days). The sites of IA were the lungs, in most cases, and brain. 7 
Diagnosis of IA in sAH remains challenging. Indeed, radiological imaging of pulmonary IA 8 
shows mainly non-specific lung infiltrates by chest CT and, more rarely (in only 36% of the 9 
cases), multiple excavated nodules or ‘classical’ condensations with a halo sign. Serum GM 10 
may be a good screening test for IA in sAH (cut-off ≥ 0.5, sensitivity of 89%, and specificity of 11 
84%). The  accuracy of this test must be validated externally because others have reported 12 
lower sensitivity and specificity in other contexts [151]. GM in BAL samples seems to have 13 
higher diagnostic accuracy. sAH complicated by IA is associated with a dramatically poor 14 
outcome despite adequate antifungal treatment.  15 
Pneumocystis pneumonia (PCP) 16 
Sporadic cases of PCP have been described in patients with sAH and concomitant 17 
corticosteroid treatment, with a 100% mortality rate [152–154]. In a prospective cohort, PCP 18 
was suspected in 8% of patients [138]. The diagnosis was based on the positivity of 19 
polymerase chain reaction (PCR) for Pneumocystis jirovecii in BAL samples, direct 20 
examination (Giemsa staining) being negative. The distinction between colonization and 21 
invasive infection was challenging due to poor general condition of the patients and non-22 
specific CT scan lung lesions.  23 
Invasive candidiasis and others 24 
The rate of diagnosis of invasive candidiasis, mainly candidemia, in sAH varies between 2% 25 
and 8% [138,150]. The accuracy of the 1,3-β-D-glucan assay in the diagnosis of invasive 26 
candidiasis is currently unknown in patients with liver disease making its utility in clinical 27 
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practice uncertain. The prognosis of candidemia and other invasive candidiasis in sAH is 1 
extremely poor with exceptional case of survival [138,155]. Some isolated cases of 2 
mucormycosis, cryptococcosis, and fusariosis have been reported in sAH [150]. 3 
Viral infections 4 
Seven cases of cytomegalovirus (CMV) pneumonia have been reported in patients with sAH, 5 
five of them concomitantly with PCP, with fatal outcomes [152–154]. Herpes simplex virus 6 
(HSV) pneumonia has also been reported in 3 cases [156,157]. Data remain indicative, but 7 
considering diagnostic challenges of CMV or HSV pneumonia, occurrence may be largely 8 
underestimated, highlighting the need for systematic and invasive screening. 9 
Treatment 10 
Antibiotic strategies 11 
Early diagnosis and adequate empirical antibiotic treatment of bacterial infections is the 12 
cornerstone in the management of patients with alcoholic cirrhosis or severe alcoholic 13 
hepatitis given their high risk of developing severe sepsis, ACLF, and death [13,15,16,132]. 14 
Several studies have demonstrated that delays in the administration of proper antibiotics has 15 
a prohibitive price in terms of mortality in cirrhotic patients with severe infections (increase in 16 
the risk of death of 8%-10% per hour of delay) [158,159]. The emergence and spread of 17 
antibiotic resistance, a problem that is especially relevant in patients with cirrhosis, requires 18 
the delineation of new first-line antibiotic strategies in this population [125,160]. In the current 19 
epidemiological scenario, initial antibiotic schedules should be tailored according to different 20 
factors including the severity of infection, recent or current antibiotic exposure, presence or 21 
absence of risk factors of MDROs (previous colonization; antibiotic treatment ≥ 5 days in the 22 
last 3 months; hospitalization ≥ 5 days in the last 3 months, nursing-home; long-term 23 
antibiotic prophylaxis), and the local epidemiological pattern of antibiotic resistance. Third-24 
generation cephalosporins and quinolones are frequently ineffective in nosocomial and 25 
healthcare-associated infections due to the increasing rate of MDROs. Empirical treatment in 26 
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the population at high risk of infection by MDROs requires the use of broad-spectrum 1 
antibiotics (i.e. carbapenems or tigecycline) or of drugs active against specific resistant 2 
bacteria. 3 
Currently recommended empirical antibiotic strategies  4 
Third-generation cephalosporins and amoxicillin-clavulanic acid, the gold-standard empirical 5 
antibiotic treatment for many of the infections occurring in cirrhosis in the past, now may have 6 
limited efficacy. Current guidelines only recommend the use of these β-lactams in infections 7 
and areas with low risk of antibiotic resistance [16]. In this setting, third-generation 8 
cephalosporins are recommended in community-acquired infections and piperacillin-9 
tazobactam in nosocomial episodes. Empirical antibiotic therapy of healthcare-associated 10 
(HCA) infections should be decided according to the severity of infection: patients with risk 11 
factors for MDROs or with severe sepsis or shock should receive the schedules proposed for 12 
nosocomial infections (Table 3) [16,161].  13 
Antibiotic strategies in areas with high rates of MDROs are far more complex. As mentioned 14 
before, classical β-lactams (third-generation cephalosporins and amoxicillin-clavulanic acid) 15 
are only recommended in non-severe infections acquired in the community. In severe HCA 16 
or community-acquired infections, especially if the patient has additional risk factors for 17 
antibiotic resistance, and in nosocomial infections empirical strategies must include drugs 18 
active against MDROs (Table 3). In these infections, antibiotics should be selected according 19 
to two major parameters: the local epidemiological pattern of antibiotic resistance and the 20 
type of antibiotics to which the patient has recently been exposed. In areas with a high 21 
prevalence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL), 22 
carbapenems should be started empirically (Table 3). The addition of antibiotics active 23 
against Gram-positive MDROS is recommended in areas with a relevant rate of infections 24 
caused by vancomycin-susceptible enterococci (VSE), vancomycin-resistant enterococci 25 
(VRE), or methicillin-resistant Staphylococcus aureus (MRSA). In patients with clinical 26 
improvement within 48-72 hours and a known pathogen, immediate tailoring of empirical 27 
antibiotics is recommended in order to prevent further antibiotic resistance [15,125,160,161]. 28 
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Antibiotic strategies for extensively drug-resistant bacteria 1 
Extensively drug-resistant (XDR) bacteria are especially difficult to treat since currently 2 
available therapeutic options are very limited, with very few new agents in development. 3 
Carbapenemase-producing Enterobacteriaceae can be susceptible to tigecycline, a drug also 4 
active against MRSA, VSE, VRE, and ESBL-producing Enterobacteriaceae. Some experts 5 
recommend combining tigecycline at high doses with carbapenem in a continuous infusion to 6 
treat this XDR strain [125,161].  A new cephalosporin-β-lactamase inhibitor combination, 7 
ceftazidime-avibactam, is active against different types of carbapenemase-producing 8 
Enterobacteriaceae [125]. Avibactam inactivates class A (KPC) and D (OXA-48) 9 
carbapenemases, but lacks activity against Enterobacteriaceae producing metallo-β-10 
lactamases (Verona integrin-encoded [VIM] and New Delhi metallo-β-lactamases [NDM]). In 11 
these latter XDR strains, combined treatments including aztreonam should be evaluated 12 
[162]. 13 
Severe infections caused by MDR Pseudomonas aeruginosa (resistant to carbapenems, 14 
ceftazidime, and quinolones) usually required in the past the combination of IV 15 
amikacin/tobramycin or colistin plus a carbapenem/ceftazidime (needed as synergistic 16 
antibiotics in spite of antibiotic resistance). Ceftolozane-tazobactam is a new antibiotic 17 
combination active against this XDR bacteria. VRE should be treated with linezolid, 18 
daptomycin, or tigecycline [161].   19 
Antifungal treatments 20 
Invasive aspergillosis (IA) 21 
The recognized first-line treatment for IA is voriconazole [163]. Experts suggest a 22 
combination of voriconazole and an echinocandin, i.e. caspofungin, for severe 23 
microbiologically documented IA in immunocompromised patients [164]. Liposomal 24 
amphotericin B is an alternative treatment when voriconazole is not tolerated or 25 
contraindicated. Liposomal amphotericin B is nephrotoxic and renal function is crucial in the 26 
prognosis of sAH [165,166]. Voriconazole induces frequently transient self-limited 27 
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hepatotoxicity but several cases of acute liver failure attributed to voriconazole have been 1 
reported [167]. Currently, it is not known if alcoholic liver diseases or advanced liver failure 2 
increase the risk of hepatotoxicity but good outcomes are sometimes described in patients 3 
with liver insufficiency and IA treated with voriconazole [168]. In the setting of sAH, a 4 
transplant-free mortality rate of 100% was observed despite different adequate antifungal 5 
regimens [138]. Success with a combination of liposomal amphotericin B and caspofungin 6 
was reported in a patient with sAH and probable IA [169]. 7 
Pneumocystis pneumonia (PCP) 8 
Trimethoprim-sulfamethoxazole (TMP-SMX) is the treatment of choice for PCP [170]. There 9 
are limited data on the efficacy of adjunctive corticosteroids for the treatment of PCP in HIV-10 
uninfected patients [171,172]. One report of seven patients with sAH and PCP described a 11 
100% mortality rate despite adequate treatment with TMP-SMX [153]. 12 
Invasive Candidiasis 13 
A diagnosis of invasive candidiasis in patients with sAH requires a prompt initiation of an 14 
echinocandin (anidulafungin, caspofungin, or micafungin) [173]. Due to the emergence of 15 
resistant organisms, such as Candida glabrata and C. krusei, fluconazole becomes a second 16 
choice, in particular in severely ill patients. In contrast to caspofungin, the pharmacokinetics 17 
of anidulafungin are unaffected in Child-Pugh B or C cirrhosis and classical doses (200 mg 18 
day 1 and then 100 mg per day intravenously) are appropriate [174].  19 
Prevention 20 
As infection is frequently due to translocation of intestinal Gram-negative bacteria, prevention 21 
is usually based on selective intestinal decontamination with a fluoroquinolone (e.g., 22 
norfloxacin, ciprofloxacin) administered in patients with a high risk of developing bacterial 23 
infection. This includes patients with acute variceal hemorrhage, patients who recover from 24 
an SBP episode, and patients with ascitic fluid protein concentration below 10-15 g/L. 25 
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Established indications for antibiotic prophylaxis 1 
Acute variceal hemorrhage  2 
In this context, antibiotic prophylaxis reduces the incidence of severe infection (SBP and/or 3 
septicemia) and decreases mortality [175]. Oral norfloxacin (800 mg/day for 7 days) is 4 
commonly used [176]. The alternative could be intravenous ceftriaxone (1 g/day for 7 days) 5 
in patients with advanced cirrhosis (at least two of the following: ascites, severe malnutrition, 6 
encephalopathy, or jaundice) [177].  7 
Recovery of an SBP episode  8 
After an episode of SBP, secondary prophylaxis using oral norfloxacin (400 mg/day) 9 
decreases the recurrence of SBP from ~70% to 20% [178]. The impact of secondary 10 
prophylaxis on survival is unknown. 11 
Primary antibiotic prophylaxis  12 
There are 4 double-blind, randomized placebo-controlled trials of prolonged fluoroquinolone 13 
therapy in the context of primary prophylaxis in cirrhosis with a majority of alcohol etiology 14 
(Table 4) [179–182]. The 4 trials enrolled patients with ascitic fluid protein concentration 15 
below 15 g/L (i.e., patients at risk of SBP). However, the primary end point of these trials 16 
differed across studies. The primary end point was primary prophylaxis of SBP in 2 studies 17 
[179,182], primary prophylaxis of Gram-negative bacteria-related infection in another [180] 18 
and mortality in the final study [181] (Table 4). These findings show that the objectives of 19 
primary antibioprophylaxis have not yet been clearly established, even if there was a 20 
consensus to enroll patients at risk of developing SBP. Moreover, only 2 studies out 4 found 21 
that quinolone administration decreased the risk of SBP [179,181] and only 2 studies out 4 22 
found a decrease in mortality with the antibiotic [181,182]. Finally, in each trial, the total 23 
number of enrolled patients was small, ranging from 60 to 107. A small sample size 24 
combined with low adherence and retention (a hallmark of studies enrolling patients with 25 
advanced cirrhosis) may make “positive” or “negative” results questionable. Therefore, it is 26 
difficult to draw firm conclusions from these 4 trials, in particular about patients who would 27 
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benefit from primary antibioprophylaxis. A large double-blind, randomized, placebo-controlled 1 
trial of norfloxacin in patients with Child-Pugh class C cirrhosis has been recently completed 2 
(NORFLOCIR ClinicalTrials.gov number, NCT01037959). Results of this trial will help to 3 
clarify the indications for primary antibiotic prophylaxis in patients with advanced cirrhosis. 4 
Issues with long-term antibiotic therapy 5 
There is no consensus on the duration of long-term oral antibiotic therapy in the prevention of 6 
the first episode of SBP or its recurrence. However, antibiotic therapy is associated with the 7 
emergence of resistant organisms [128]. Thus, alternative approaches are needed. Results 8 
of a large double-blind RCT showed that oral pentoxifylline administration (1,200 mg/day) 9 
significantly decreased the risk of bacterial infection in patients with advanced cirrhosis [141]. 10 
Short-term administration of subcutaneous granulocyte colony-stimulating factor (5 µg/Kg 11 
every 12-24h alone or in combination with darbopoietin (a synthetic analog of erythropoietin) 12 
has shown to improve liver function, reduce the incidence of severe sepsis and increase 13 
survival in comparison to placebo in patients decompensated cirrhosis and with ACLF, many 14 
of them alcoholics, and in sAH [143,144,183]. Induction of hepatic regeneration and 15 
restoration the immune imbalance are proposed as potential mechanisms. 16 
Potential prophylaxis in corticosteroid-treated sAH 17 
Due to the high incidence of bacterial infection associated with corticosteroid treatment, 18 
antibioprophylaxis could be an attractive option for improving outcomes for patients with sAH. 19 
This strategy is currently being assessed in a multicenter RCT (ANTIBIOCOR 20 
ClinicalTrials.gov number, NCT02281929). In view of the poor prognosis for IFI despite 21 
adequate antifungal therapies, a prophylactic or preemptive treatment might be more 22 
efficient. Prospective studies should be conducted to identify the true incidence, and risk 23 
factors for invasive candidiasis, IA or PCP in corticosteroid-treated patients with sAH, and to 24 
evaluate prophylactic strategies. Then, we proposed an strategic algorithm in patients with 25 
sAH to reduce infectious complications (Figure 3). 26 
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Perspectives and area of research 1 
Systemic inflammation is the hallmark of ALD. Numerous animal experiments, not 2 
reproducing all spectrum of human ALD, support the contribution of activation of innate 3 
immune response in its progression. Logically, current therapeutic targets were based on this 4 
paradigm. On the other side, coming mainly from human translational studies, an 5 
immunoparalysis is described particularly in severe forms of ALD, as sAH. This can explain 6 
the failure of therapeutic options targeting pro-inflammatory cytokines as TNFα by inducing 7 
infection complications [70,142]. Corticosteroids remain the sole proven effective treatment in 8 
sAH and their impact on the immune system is complex. The beneficial survival effect of 9 
corticosteroids might be lessened by their impat on the infectious risk.  Glucocorticoids exert 10 
both negative and positive effects with a dynamic and bi-directional spectrum of activities on 11 
various limbs and components of the immune response [184]. They modulate genes involved 12 
in the priming of the innate immune response, while their actions on the adaptive immune 13 
response are to suppress cellular immunity and promote humoral immunity. Deciphering the 14 
effects of corticosteroids on the immune system of patients with sAH to reveal more specific 15 
therapeutic options is an urgent medical need. Such strategies have been already tested 16 
[185] but must be developed using state-of-the-art high-throughput immunological 17 
technologies. Therapeutic targets to improve immune dysfunction in patients with sAH are 18 
suggested in table 1. 19 
We must invest also in non-antibiotic strategies to prevent infections in patients with severe 20 
ALD to avoid the emergence of MDROs. The modulation of gut microbiome and the 21 
correction of increased intestinal permeability are attractive options. In exemple, the 22 
administration of enoxaparin to prevent portal vein thrombosis in Child-Pugh B-C cirrhosis 23 
reduced the occurrence of SBP and bacteremia in a RCT [186]. The mechanisms of this 24 
prevention are incompletely understood but some experimental data suggest a reduction of 25 
bacterial translocation under enoxaparin treatment.  26 
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Conclusions 1 
In conclusion, alcohol abuse, alcoholic cirrhosis and sAH are recognized as risk factors for 2 
infections. The immune defect seems to increase gradually with the severity of ALD. The 3 
leaky gut and intestinal dysbiosis, particularly described in ALD, contribute to this immune 4 
defect and infectious complications. Infection in patients with sAH is a major driver of 5 
mortality. Systematic screening of infection should be performed at admission, before the 6 
initiation of corticosteroids. The controversy about the contribution of corticosteroids in the 7 
susceptibility of infections remains. Although one study observed an increased risk of 8 
infection in patients treated with corticosteroids, this was not confirmed in a recent meta-9 
analysis and the higher risk in the STOPAH trial was conversely associated with a lower risk 10 
of death in patients treated with prednisolone. Opportunistic infections become an emergent 11 
problem, particularly in patients with sAH treated by corticosteroids. High level of suspicion 12 
with systematic screening and prompt, adequate treatment are warranted to improve 13 
outcome of those patients. Prophylactic or preemptive strategies in this high-risk population 14 
might be a preferable option due to the high short-term mortality rate despite adequate 15 
therapies but should be assessed in well-designed trials before clinical implementation.  16 
Figure legend 17 
Figure 1. 18 
Summary of the different effects of alcohol at multiple levels of the immune system. IFN, 19 
interferon; IL, interleukin; ROS, reactive oxygen species. 20 
Figure 2. 21 
Diagram about the link between immune dysfunction associated with alcohol-related liver 22 
diseases (ALD) and the susceptibility to infections and opportunistic pathogens. The 23 
exacerbation of systemic inflammation following the progression of ALD is associated with 24 
relative paralysis of immune cells to respond to further stimuli resulting in a 25 
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immunosuppressive state. DCs, dendritic cells; IL, interleukin; NK, natural killers; DCs, 1 
dendritic cells; TNF, tumor necrosis factor. 2 
Figure 3.  3 
Proposed algorithm to diagnose, to manage and to prevent infection in patients with severe 4 
alcoholic hepatitis (sAH). * Infections is considered as controlled using the following criteria: 5 
(1) for spontaneous bacterial peritonitis or bacteremia, a decrease in neutrophil count of 6 
>50% in ascitic fluid within the first 48 hours and a neutrophil count of <250/mm3 at the end 7 
of therapy; (2) for urinary tract infection, negative culture under therapy; (3) for bacteremia, 8 
negative blood culture and absence of fever; (4) for respiratory infection, combined criteria 9 
that included a decrease in C-reactive protein, absence of fever, improvement in physical 10 
examination, and no need for oxygen supply; (5) for cutaneous infection, a decrease in C-11 
reactive protein, absence of fever, and improvement in skin lesions [135]. # In 12 
bronchoalveolar lavage (BAL), the following exams should be performed: direct microscopic 13 
examination, Giemsa coloration or immunofluorescence for Pneumocystis jirovecii, bacterial 14 
and fungal cultures, galactomannan (GM), PCR for Pneumocystis jirovecii, CMV and HSV. 15 
Mycobacterial cultures should also be considered according to epidemiological setting. & We 16 
propose to stop corticosteroids when a diagnosis of infection is made except for non-17 
complicated urinary tract infection. mDF, modified Maddrey discriminant function; NAC, N-18 
acetylcystein 19 
 20 
 21 
 22 
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Tables 
Table 1. Cellular basis of immune dysfunction in sAH, associated mechanisms and possible therapeutic targets. 
Cell Type Main functional derangement Mechanism Therapeutic target 
T Lymphocytes [71] 
 
Reduced T cell IFN production 
in response to LPS 
 
Increased T cell production of 
IL-10  
Increased expression of PD1 and 
TIM-3 
• Antibodies to PDI and TIM-3 
restored function 
Monocytes and Macrophages 
[72–75] 
 
Reduced LPS-induced TNFα 
production 
 
Reduced pro-inflammatory 
cytokine secretion and bacterial 
killing 
 
 
 
Reduced pro-inflammatory 
cytokine secretion in response 
to LPS 
 
Reduced monocyte oxidative 
burst and bacterial killing 
 
Reduced HLA-DR expression 
 
 
Increased Prostaglandin E2 
 
 
 
 
 
Increased expression of MERTK 
 
 
 
Reduced gp91phox subunit of 
NADPH oxidase 
• Reduce bacterial translocation 
 
 
• PGE2 receptor antagonists 
• COX-2 inhibitors 
• Albumin infusion 
 
 
 
• Inhibition of MERTK, UNC569 
 
 
• NADPH modulators 
 
Neutrophils 
[76–78] 
Increased resting burst but 
reduced E. coli-induced 
oxidative burst and reduced 
phagocytosis 
 
Reduced bactericidal activity 
Involvement of humoral factor 
possibly LPS and TLR4 
 
 
Defect of myeloperoxidase 
release and the AKT/p38 MAP 
kinase pathway 
• Reduce bacterial translocation 
• Removal of LPS using plasma 
exchange or specific filters 
• TLR4 antagonists 
 
• TLR7/8 agonists 
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Table 2. Prevalence and incidence of infections in sAH 
N pts Prevalence 
at baseline % 
Incidence during 
follow-Up % 
Incidence in 
the control 
group 
Incidence in the 
corticosteroid-
treated group 
Follow-up duration for 
infection 
Vergis, 2017 [92] 1092 12* 31 33 29 3 months 
Moreno, 2016 [187] 133 ND * 61 NA 61 6 months 
Michelena, 2015 
[93] 162 20 44 36 52 
#
 During hospitalization 
Karakike, 2015 [137]  79 30  51 NA NA 3 months 
Park, 2014 [140] 121 6 * 8  5 12 6 months 
Gustot, 2014 [138] 94 ND 67 NA NA 3 months 
Mathurin, 2013 [11] 270 ND * 33 NA 33 6 months 
Nguyen-Khac, 2011 
[12] 174 ND * 30 NA 30 6 months 
Moreno, 2010 [188] 47 ND * 36 36 NA 1 month 
Louvet, 2009 [135] 246 26 23 NA 23 2 months 
*Exclusion of uncontrolled infections before randomization. # p<0.05 compared with placebo or no treatment. NA, not applicable; ND, not 
determined. 
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Table 3. Recommended empirical antibiotic strategies in patients with alcoholic cirrhosis or severe alcoholic hepatitis and 
bacterial infection 
 
Type of infection 
Absence of severe sepsis 
Community-acquired  
infections 
HCA and nosocomial infections 
Low prevalence of  
MDR bacteria 
High prevalence of  
MDR bacteria 
Spontaneous bacterial 
peritonitis 
 
  
IV 3rd-generation cephalosporins  
 
 
 
IV piperacillin/tazobactam   
 
 
IV meropenem ± glycopeptide or 
linezolid/daptomycin# Spontaneous bacteremia 
Urinary infections  
Pneumonia** IV 3rd-generation cephalosporins + 
oral/IV macrolide or levofloxacin 
IV meropenem/ceftazidime 
+ciprofloxacin ±glycopeptide or linezolid ¶ 
Soft tissue infections IV amoxicillin/clavulanic acid  IV meropenem/ceftazidime + 
glycopeptide or linezolid/daptomycin# 
 
 
Type of infection 
Severe sepsis or shock* 
Low prevalence of  
MDR bacteria 
High prevalence of  
MDR bacteria 
Spontaneous bacterial 
peritonitis 
 
 
IV piperacillin/tazobactam   
 
 
 
IV meropenem + glycopeptide or linezolid/daptomycin# Spontaneous bacteremia 
Urinary infections  
Pneumonia IV meropenem/ceftazidime +ciprofloxacin ±linezolid ¶ 
Soft tissue infections IV meropenem/ceftazidime + linezolid/daptomycin# 
 
*: Empirical antibiotic treatment of severe sepsis or shock will be decided considering the local rate of MDR pathogens in order to cover all 
potential pathogens. Site of infection is not considered. 
#: linezolid/daptomycin in areas with a high prevalence of vancomycin-resistant enterococci (VRE); ¶: antibiotics active against MRSA should be 
added in patients with risk factors: ventilator-associated pneumonia, previous antibiotic therapy, nasal MRSA carriage. Consider adding 
nebulized colistin or amikacin to cover MDR Pseudomonas aeruginosa in areas with high prevalence of this MDR bacteria. HCA, healthcare 
associated; MDR, multi-drug resistant.  
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Table 4. Characteristics of double-blind, randomized, placebo-controlled clinical trials of an oral quinolone for primary 
prophylaxis of infection in patients with cirrhosis 
Characteristics Study Details 
Reference Rolachon et al. [179] Grangé et al. [180] Fernandez et al. [181] Terg et al. [182] 
Intervention Ciprofloxacin (750 mg 
per os, once a week, for 
6 months) 
Norfloxacin (400 mg per day for 
6 months)  
Norfloxacin (400 mg per 
day for 12 months)  
Ciprofloxacin (500 mg per day, for 
12 months) 
Inclusion criteria AF protein concentration 
≤15 g/L 
AF protein concentration <15 g/L AF protein concentration 
<15 g/L and advanced 
cirrhosis* 
AF protein concentration < 15 g/L 
Primary end point Primary prevention of 
SBP** 
Primary prevention of Gram-
negative bacterial infections 
3-month and 1-year 
probability of survival 
Primary prevention of SBP 
Number of patients 
   Quinolone 
   Placebo 
 
28 
32 
 
53 
54 
 
35 
33 
 
50 
50 
Proportion of alcoholic 
cirrhosis, n (%) 
55 (92) 93 (87) 36 (53) NA 
Bacterial infection (% of patients) 
   Any    
 
 
 
  
37 
 
      Quinolone 
      Placebo 
14 
34 
13 
24 
40 
 
58 
16 
32** 
   SBP 
      Quinolone 
      Placebo 
 
4 
22* 
 
0 
9 
 
 
6 
 
30*** 
 
4 
14 
   Caused by Gram-
negative bacteria 
      Quinolone 
      Placebo 
 
 
4 
0 
 
 
0 
11 
 
 
 
37 
 
18 
 
 
NA 
NA 
Mortality rate (%) 
   By 3 months 
      Quinolone 
      Placebo 
 
- 
- 
 
- 
- 
 
 
6 
 
30*** 
 
- 
- 
   By 6 months 
      Quinolone 
      Placebo 
 
14 
19 
 
15 
18 
 
 
- 
 
- 
 
- 
- 
   By 1 year 
      Quinolone 
 
- 
 
- 
 
 
29 
 
 
14 
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      Placebo - - 39**** 34*** 
Abbreviations: AF, ascitic fluid; SBP, spontaneous bacterial peritonitis; NA: Not available. 
*Advanced cirrhosis was defined as follows: advanced liver failure (Child–Pugh score ≥ 9 points with serum bilirubin level ≥ 3 mg/dL) or 
impaired renal function (serum creatinine level ≥ 1.2 mg/dL, blood urea nitrogen level ≥ 25 mg/dL, or serum sodium level ≤ 130 mEq/L) 
**Only 2 patients in the ciprofloxacin group and 5 in the placebo group had had prior episode of SBP. 
***p<0.05 quinolone vs. placebo 
****The Kaplan-Meier estimate of 1-year mortality was 48% in the norfloxacin group and 60% in the placebo group (p=0.05). 
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